EyePoint Pharmaceuticals
Stock Forecast, Prediction & Price Target
EyePoint Pharmaceuticals (EYPT) stock Price Target by analysts
$22
Potential upside: 99.27%
EyePoint Pharmaceuticals price prediction
What is EyePoint Pharmaceuticals stock analysts` prediction?
EyePoint Pharmaceuticals stock forecast: Based on 1 Wall Street analysts` predicted price targets for EyePoint Pharmaceuticals in the last 3 months, the avarage price target is $22, with a high forecast of $NaN. The average price target represents a 99.27% change from the last price of $11.04.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
EyePoint Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given EyePoint Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Yi Chen H.C. Wainwright | 0% 0/2 | 11 months ago | $22 99.27% upside | $11.59 | StreetInsider | Previous targets (1) |
Yi Chen H.C. Wainwright | 0% 0/2 | over 1 year ago | $30 171.73% upside | $12.17 | StreetInsider | Previous targets (1) |
Graig Suvannavejh Mizuho Securities | 0% 0/1 | over 1 year ago | $30 171.73% upside | $11.2 | StreetInsider | Previous targets (0) |
Unknown H.C. Wainwright | N/A | about 3 years ago | $25 126.44% upside | $10.22 | Benzinga | N/A |
EyePoint Pharmaceuticals Financial Estimates
EyePoint Pharmaceuticals Revenue Estimates
EyePoint Pharmaceuticals EBITDA Estimates
EyePoint Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $36.93M N/A | $41.40M 12.08% | $46.01M 11.14% | Avg: $13.34M Low: $2.93M High: $22.10M avg. -70.99% | Avg: $9.57M Low: $5.71M High: $12.67M avg. -28.26% | Avg: $69.38M Low: $41.38M High: $91.82M avg. 624.66% | Avg: $312.90M Low: $186.63M High: $414.05M avg. 350.94% |
Net Income
% change YoY
| $-63.91M N/A | $-124.51M -94.80% | $-70.79M 43.14% | Avg: $-173.61M Low: $-177.01M High: $-90.25M avg. -145.23% | Avg: $-214.61M Low: $-148.17M High: $-105.81M avg. -23.61% | Avg: $-100.69M Low: $-143.01M High: $-47.86M avg. 53.08% | Avg: $20.15M Low: $9.58M High: $28.62M avg. 120.01% |
EBITDA
% change YoY
| $-52.52M N/A | $-74.75M -42.32% | $-69.00M 7.69% | Avg: $-13.34M Low: $-22.10M High: $-2.93M avg. 80.65% | Avg: $-9.57M Low: $-12.67M High: $-5.71M avg. 28.26% | Avg: $-69.38M Low: $-91.82M High: $-41.38M avg. -624.66% | Avg: $-312.90M Low: $-414.05M High: $-186.63M avg. -350.94% |
EPS
% change YoY
| -$2.22 N/A | -$3.34 -50.45% | -$1.82 45.50% | Avg: -$3.18 Low: -$4.55 High: -$2.32 avg. -74.49% | Avg: -$3.38 Low: -$3.81 High: -$2.72 avg. -6.47% | Avg: -$2.59 Low: -$3.68 High: -$1.23 avg. 23.45% | Avg: $0.52 Low: $0.25 High: $0.74 avg. 120.01% |
Operating Expenses
% change YoY
| $84.03M N/A | $112.01M 33.29% | $115.04M 2.70% | Avg: $20.48M Low: $4.50M High: $33.93M avg. -82.19% | Avg: $14.69M Low: $8.76M High: $19.44M avg. -28.26% | Avg: $106.50M Low: $63.52M High: $140.93M avg. 624.66% | Avg: $480.27M Low: $286.45M High: $635.53M avg. 350.94% |
FAQ
What is EyePoint Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 1.05% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is -177.01M, average is -173.61M and high is -90.25M.
What is EyePoint Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 219.08% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is $2.93M, average is $13.34M and high is $22.10M.
What is EyePoint Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.62% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is -$4.55, average is -$3.18 and high is $-2.32.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering EyePoint Pharmaceuticals stock. The most successful analyst is Yi Chen.